Our findings differ from the study of Chou et al.,30 who reported no significant impact of TET2 mutation on OS among AML patients with favorable molecular genotypes (NPM1mut/FLT3‐ITD(−) or CEBPAdouble). This evidence concerns the gene FLT3 and acute myeloid leukemia.